EntreMed Presents Phase 2 Results for Panzem(R) Capsules in Multiple Myeloma Monday June 4, 7:00 am ET
“Patients Remain on Study for Over Four Years Without Disease Progression”
“Progression free survival (PFS) rates were 24%, 17% and 11% for all patients at 1, 2, and 3 years. Five patients continue to receive Panzem® Capsules, including three patients with plateau phase disease who have been on study for over four years without disease progression. EntreMed has also received orphan drug designation for 2ME2 in multiple myeloma from the FDA.”
Market Data 
Markets 
AI
